Results
|
|
1.
|
Reply to E.J. Moylan et al. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(6):606-7, 2014 Feb 20.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Geyer CE Jr, Swain SM, Tang G
|
|
|
2.
|
Reply to a. Avan et Al. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(15):1712, 2015 May 20.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baselga J, Clark E, Kiermaier A, Swain S
|
|
|
3.
|
Treatment of HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(20):1964-5, 2015 May 14.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baselga J, Clark E, Swain SM
|
|
|
4.
|
|
|
|
5.
|
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. MedStar authors:
Year: 2016
Citation: - Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Anderson SJ, Cecchini RS, Costantino JP, Geyer CE Jr, Jeong JH, Lembersky BC, Paterson AH, Rastogi P, Romond EH, Swain SM, Tang G, Wolmark N
|
|
|
6.
|
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. MedStar authors:
Year: 2012
Citation: - Lancet. 379(9814):432-44, 2012 Feb 4.
Institution: - Washington Cancer Institute
Medline publication type:
- Comparative Study
- Journal Article
- Meta-Analysis
- Research Support, Non-U.S. Gov't
All authors: - Albain K, Bergh J, Clarke M, Cutter D, Darby S, Davies C, Di Leo A, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Godwin J, Gray R, McGale P, Pan HC, Peto R, Piccart M, Pritchard K, Swain S, Taylor C, Wang YC
|
|
|
7.
|
Pertuzumab: increasing the options. MedStar authors:
- Nunes, Raquel
- Swain, Sandra M
Citation: - Oncology (Williston Park). 28(3):199, 204, 210, 2014 Mar.
Institution: - Washington Cancer Institute
Medline publication type:
- Comment
- Journal Article
- Research Support, Non-U.S. Gov't
|
|
|
8.
|
Pazopanib for the treatment of breast cancer. [Review] MedStar authors:
Year: 2012
Citation: - Expert Opinion on Investigational Drugs. 21(2):217-25, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Review
All authors: - Amiri-Kordestani L, Swain SM, Tan AR
|
|
|
9.
|
|
|
|
10.
|
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. MedStar authors:
Year: 2016
Citation: - Annals of Surgical Oncology. 24(7):1853-1860, 2017 Jul
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Kidwell KM, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA, Zoon CK
|
|
|
11.
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. MedStar authors:
Year: 2012
Citation: - Lancet Oncology. 13(7):734-42, 2012 Jul.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Anderson SJ, Baez-Diaz L, Brufsky AM, Costantino JP, Dakhil S, Falkson CI, Fehrenbacher L, Geyer CE Jr, Gralow JR, King KM, Lad T, Lembersky BC, Mamounas EP, Paterson AH, Perez EA, Robidoux A, Swain SM, Weir LM, Wolmark N, Zheng P
|
|
|
12.
|
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Colon-Otero G, Davidson NE, Geyer CE Jr, Gralow J, Jeong JH, Mamounas E, Martino S, Perez EA, Rastogi P, Romond EH, Sledge G, Suman VJ, Swain SM, Winer EP, Wolmark N, Zujewski JA
|
|
|
13.
|
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. MedStar authors:
Year: 2014
Citation: - Annals of Oncology. 25(6):1116-21, 2014 Jun.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Cortes J, Im YH, Lee LF, Miles D, Quah C, Swain SM
|
|
|
14.
|
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors:
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D
|
|
|
15.
|
|
|
|
16.
|
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - BMC Cancer. 14:307, 2014.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Beattie M, Hurvitz S, Jahanzeb M, Kaufman PA, Lai C, Masaquel A, Mason G, O'Shaughnessy J, Rugo HS, Swain S, Tripathy D, Yoo B
|
|
|
17.
|
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. MedStar authors:
Year: 2017
Citation: - JAMA Oncology. 3(3):335-341, 2017 Mar 01
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Bandos H, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Johnson NL, Kim SR, Lipchik C, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
|
|
18.
|
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. MedStar authors:
Year: 2015
Citation: - Lancet Oncology. 16(9):1037-48, 2015 Sep.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Liu Q, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
19.
|
Pertuzumab for the treatment of breast cancer. [Review] MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Year: 2014
Citation: - Cancer Investigation. 32(8):430-8, 2014 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
|
|
|
20.
|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors:
Year: 2013
Citation: - Oncologist. 18(3):257-64, 2013.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM
|
|
|
21.
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM
|
|
|
22.
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. MedStar authors:
Year: 2013
Citation: - Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Bandos H, Blackmon NL, Bohn OL, Burandt E, Costantino JP, Fehrenbacher L, Fumagalli D, Gavin PG, Geyer CE Jr, Goldstein LC, Horne ZD, Jeong JH, Kim C, Kim SI, Kim SR, Lee A, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Reilly ML, Remillard MY, Romond EH, Sneige N, Swain SM, Tanaka N, Taniyama Y, Wickerham DL, Wolmark N
|
|
|
23.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
Year: 2013
Citation: - Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
|
|
|
24.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(8):724-34, 2015 Feb 19.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
25.
|
|
|
|
26.
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Blackmon NL, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Kim SR, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
|
|
27.
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. MedStar authors:
Year: 2013
Citation: - Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Atkins JN, Azar CA, Biggs DD, Brufsky AM, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE Jr, Levine EA, Mamounas EP, Northfelt DW, Paik S, Polikoff JA, Provencher L, Rastogi P, Robidoux A, Swain SM, Tang G, Wolmark N, Zapas JL
|
|
|
28.
|
|
|
|
29.
|
|
|
|
30.
|
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(16):4233-4241, 2020 08 15.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Bandos H, Brauer HA, Geyer CE Jr, Goerlitz DS, Harris BT, Lucas PC, Mamounas EP, Rastogi P, Ren Y, Robidoux A, Swain SM, Tang G, Wolmark N
|
|
|
31.
|
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. [] MedStar authors:
Year: 2015
Citation: - Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bhatt K, Bury MJ, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Goel R, Jacobs SA, Johannes H, Julian TB, Mamounas EP, Provencher L, Rastogi P, Robidoux A, Stella PJ, Swain SM, Tan AR, Thirlwell MP, Wolmark N
|
|
|
32.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors:
Year: 2013
Citation: - Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J
|
|
|
33.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
Year: 2013
Citation: - Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
|
|
|
34.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
35.
|
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. MedStar authors:
- McCarron, Edward C
- Swain, Sandra M
Year: 2018
Citation: - Journal of the National Cancer Institute. 110(2), 2018 Feb 01
Institution:
- MedStar Franklin Square Medical Center
- Washington Cancer Institute
Medline publication type:
All authors: - Bandos H, Brufsky AM, Fehrenbacher L, Ganz PA, Julian TB, Margolese RG, McCarron EC, Melnikow J, Rivera DR, Sturtz K, Swain SM, Wade JL 3rd
|
|
|
36.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
|
|
37.
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors:
Year: 2012
Citation: - New England Journal of Medicine. 366(4):310-20, 2012 Jan 26.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
38.
|
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
Year: 2022
Citation: - Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
|
|
|
39.
|
Avastin withdrawal symptoms. MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Citation: - Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Editorial
- Research Support, Non-U.S. Gov't
|
|
|
40.
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(12):1183-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N
|
|
|
41.
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. MedStar authors:
Year: 2012
Citation: - Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Comparative Study
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Allred DC, Anderson SJ, Costantino JP, Geyer CE Jr, Julian TB, Land SR, Mamounas EP, Nagtegaal ID, Paik S, Swain SM, Wickerham DL, Wolmark N
|
|
|
42.
|
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. MedStar authors:
- Swain, Sandra M
- Zapas, John L
Year: 2017
Citation: - Journal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Atkins JN, Biggs DD, Brufsky AM, Cecchini RS, Fehrenbacher L, Flynn PJ, Ganz PA, Geyer CE Jr, Gross HM, Jeong JH, Mamounas EP, Polikoff J, Rastogi P, Romond EH, Seay TE, Swain SM, Wade JL 3rd, Wahl TA, Wolmark N, Zapas JL
|
|
|
43.
|
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Herbolsheimer, Pia M
- Lynce, Filipa
- Mete, Mihriye
- Nunes, Raquel
- Shara, Nawar M
- Swain, Sandra M
- Wray, Lynette
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):285-93, 2016 Jan.
Institution:
- MedStar Health Research Institute
- MedStar Health Research Institute
- MedStar Health Research Institute
- MedStar Washington Hospital Center
- MedStar Washington Hospital Center
- Washington Cancer Institute
- Washington Cancer Institute
- Washington Cancer Institute A
- Washington Cancer Instituteia
Department:
- MedStar Heart Institute
- MedStar Heart Institute
Medline publication type:
All authors: - Asch FM, Barac A, Herbolsheimer P, Isaacs C, Lynce F, Mete M, Nardacci MP, Nunes RA, Peshkin BN, Shara NM, Smith KL, Swain SM, Warren R, Wray L
|
|
|
44.
|
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Lynce, Filipa
- Swain, Sandra M
Year: 2017
Citation: - Oncologist. 22(5):518-525, 2017 May
Institution:
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Medline publication type:
All authors: - Asch FM, Barac A, Dang C, Isaacs C, Lynce F, Smith KL, Swain SM, Tan MT
|
|
|
45.
|
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Cunningham, A
- Gallagher, Christopher
- Hofmeyer, Mark
- Srichai, M B
- Swain, Sandra M
Year: 2019
Citation: - Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
- MedStar Health
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
|
